Table 2.
Patient characteristics with or without HCC recurrence after DAA therapy
|
Patients with HCC recurrence (n = 217) |
Patients without HCC recurrence (n = 242) |
P‐value | |
|---|---|---|---|
| Age before DAA therapy (y) | 74.9 ± 7.7 | 75.0 ± 7.5 | 0.9327 |
| Sex (male/female) | 138/79 | 131/111 | 0.0399 |
| AST level before DAA therapy (IU/L) | 61.6 ± 34.7 | 55.9 ± 27.2 | 0.0518 |
| ALT level before DAA therapy (IU/L) | 50.2 ± 35.8 | 47.0 ± 28.6 | 0.2883 |
| GGTP level before DAA therapy (IU/L) | 47.4 ± 39.0 | 50.0 ± 65.8 | 0.6204 |
| Platelet count before DAA therapy (×104/μL) | 10.0 ± 4.8 | 11.4 ± 5.0 | 0.0021 |
| AFP level before DAA therapy (ng/mL) | 36.3 ± 88.3 | 21.6 ± 39.0 | 0.0196 |
| APRI before DAA therapy | 2.54 ± 1.85 | 2.12 ± 1.74 | 0.0117 |
| FIB‐4 index before DAA therapy | 7.70 ± 4.00 | 6.56 ± 4.23 | 0.0032 |
| Geno/serotype (1/2/1+2/unknown) | 190/26/0/1 | 217/23/1/1 | 0.3982 |
| Habitual alcohol intake (presence/absence/unknown) | 32/153/32 | 23/180/39 | 0.0923 |
| Diabetes mellitus (presence/absence/unknown) | 59/150/8 | 69/165/8 | 0.7707 |
| Fatty liver (presence/absence/unknown) | 16/154/47 | 17/167/58 | 0.9555 |
| Cirrhosis (presence/absence/unknown) | 169/48/0 | 154/87/1 | 0.0011 |
| Number of curative treatments for HCC before DAA therapy (1/2/3 or more/unknown) | 98/46/71/2 | 164/42/34/2 | <0.0001 |
Results are expressed as mean ± SD.
AFP, alpha‐fetoprotein; ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet count ratio index; AST, aspartate aminotransferase; DAA, direct‐acting antiviral agents.; FIB‐4 index, Fibrosis‐4 index; GGTP, gamma‐glutamyl transpeptidase; HCC, hepatocellular carcinoma